期刊文献+

STAT1/SOCS1在高迁移率族蛋白1诱导的大鼠滑膜细胞中的表达 被引量:1

The expression of STATI/SOCS1 on the rat synoviocytes induced by high mobility group box
原文传递
导出
摘要 目的探讨高迁移率族蛋白fHMGB)I对滑膜细胞增殖的影响及机制。方法①常规培养的滑膜细胞,随机分为正常对照组和肿瘤坏死因子(TNF)-α组,培养6、12h和24h,反转录-聚合酶链反应(RT—PCR)和免疫细胞化学法(ICC)检测HMGB1mRNA及蛋白在滑膜细胞中的表达变化;②常规培养的滑膜细胞,随机分为正常对照组、HMGB1组,分别培养6、12h和24h,RT—PCR检测磷酸化信号转导和转录激活因子(p—STATI)mRNA表达;ICC和流式细胞术(FCM)检测p—STAT1、细胞激酶信号抑制剂(SOCSI)蛋白的表达;ICC检测PCNA蛋白的表达。结果①TNF—α刺激6、12、24h显著上调HMGB1mRNA的表达[0.86,0.92,1.06vs0.70,P〈0.01];其蛋白表达亦增强,HMGB1蛋白不仅表达于细胞核,而且出现于胞质中;②HMGB1作用6、12、24h显著增强STAT1mRNA及蛋白的表达量[0.30,0.69,1.05vs0.24,P〈0.01)]及[1.34±0.09,1.55±0.16,1.74±0.13vs1.00±0.15,P〈0.01];SOCS1蛋白量分别为1.43±0.10、1.58±0.05和1.24±0.15,呈先升高后下降。③p—STATI与SOCS1蛋白表达呈负相关(r=-0.484,P=0.04)。结论HMGB1是滑膜细胞增殖过程中的重要细胞因子,其可能通过上调STAT1的表达和活性,促进细胞增殖。 Objective To investigate the effect and possible mechanisms of high mobility group box (HMGB) 1 on the proliferation of RSC-364 synoviocytes. Methods (1) RSC-364 cells stimulated by 10 μg/L TNF-α and cells of the normal control groups were collected at 6, 12, 24 h respectively in vitro. HMGBhnRNA and protein was detected by reverse transcription polymerase chain reaction (RT-PCR) and immunocytochemistry (ICC); (2) RSC-364 cells induced by 10 μg/L HMGB1 were collected in 6, 12, 24 h respectively, so did normal control group cells in vitro. The expression of signal transducer and activator of transcription (STAT) mRNA 1 was detected by RT-PCR. The expression of STATland SOCS1 proteins were detected by ICC and flow cytometry analysis (FCM). The expression of PCNA was detected by ICC. Results Compared with the control group, TNF-α markedly up-regulated HMGB1 mRNA at 6, 12, 24 h respectively [0.86, 0.92, 1.06 vs 0.70, P〈0.01 ], as well as protein expressfon level. Positive signal of HMGB1 proteins was not only expressed in nuclear but also in cytoplasm after stimulation. (2) Compared with normal group, HMGB1 increased the expression of P-STAT1 mRNA and protein at 6, 12, 24 h respectively [0.30, 0.69, 1.05 vs 0.24, P〈0.01 ] and [ 1.34±0.09, 1.55±0.16, 1.74±0.13 vs 1.00±0.15, P〈0.01]. The expression of SOCS1 protein increased significantly in HMGB1 group at 6 and 12 hours ( 1.43±0.10 vs 1.58±0.05), but it decreased at 24 hours (1.24±0.15). (3) The expression of p-STAT1 protein was negatively correlated with that of SOCS1 protein. Conclusion HMGB1 appears to be an important mediator in the proliferation of RSC-364 cells, partly by up-regulating the expression and activity of p-STAT1.
出处 《中华风湿病学杂志》 CAS CSCD 2008年第7期473-476,I0003,共5页 Chinese Journal of Rheumatology
关键词 高迁移率族蛋白 滑膜细胞 信号转导和转录激活子1 细胞激酶信号-1抑制剂 High mobility group box chromosomal protein Synoviocytes Signal transducer and activator of transcription 1 Suppressor of cytokine signaling 1
  • 相关文献

参考文献10

  • 1侯勇,张奉春,黄烽,吴东海,鲍春德,倪立青,姚晨.Infliximab治疗类风湿关节炎的随机双盲平行多中心临床试验[J].中华风湿病学杂志,2006,10(11):658-663. 被引量:34
  • 2Harris HE, Andersson U. The nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immnunol, 2004, 34: 1503-1512.
  • 3Anderssonb U, Harris HE. HMGB1 is a potent trigger of arthritis. J Intern Med, 2004, 255: 344-350.
  • 4Morkve O, Learun OD. Flow cytometric measurement of P53 protein expression and DNA content in paraffin embedded tissue from bronchial carcinomas .Cytometry, 1991, 12: 438-444.
  • 5Pullerits R, Jonsson IM , Verdrengh M, et al. High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis.Arithritis Rheum, 2003 ,48: 1693-1700.
  • 6周亚欧,左晓霞,罗卉,龚艳晖,肖献忠.高迁移率族蛋白-1在大鼠佐剂性关节炎发病中的作用研究[J].中华风湿病学杂志,2006,10(11):664-667. 被引量:6
  • 7Levy DE, Damell JE. STATs transcriptional control and biological impact. Nat Rev Mol Cell Biol, 2002, 3: 651-662.
  • 8Aaronson DS, Horvath CM. A road map for those who know Jak-STAT. Science, 2002, 296: 1653-1655.
  • 9Kasperkovitz PV, Verbeet NL, Smeets TJ, et al. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis, 2004,63: 233-239.
  • 10Yoshimura A, Nishinakamura H, Matsumura Y, et al. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther, 2005, 7:100-110.

二级参考文献32

  • 1胡大伟,鲍春德,陈顺乐,古洁若,栗占国,孙凌云,韩星海,倪立青.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗类风湿关节炎双盲随机多中心对照临床研究[J].中华风湿病学杂志,2005,9(11):664-668. 被引量:86
  • 2Shealy DJ,Wooley PH,Emmell E,et al.Anti-TNF-α antibody allows healing of joint damage in polyarthritic transgenic mice.Arthritis Res,2002,4:R7.
  • 3Siegel SA,Shealy DJ,Nakada MT,et al.The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo.Cytokine,1995,1:15-25.
  • 4D'Haens DR.Infliximab as disease-modifying therapy.Eur'J Gastroenterol Hepatol,2003,15:233-237.
  • 5Maini R,St Clair EW,Breedveld F,et al.Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:a randomised phase Ⅲ trial.Lancet,1999,354:1932-1939.
  • 6Lipsky PE,van der Heijde DMFM,St Clair EW,et al.Infliximab and methotrexate in the treatment of rheumatoid arthritis.N Engl J Med,2000,343:1594-1602.
  • 7Harriman G,Harper LK,Schaible TH.Summary of clinical trials in rheumatoid arthritis using infliximab,an anti-TNF-α treatment.Ann Rheum Dis,1999,58:161-164.
  • 8Maini RN,Breedveld FC,Kalden JR,et al.Sustained improvement over two years in physical function,structural damage,and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.Arthritis Rheum,2004,50:1051-1065.
  • 9Breedveld FC,Emery P,Keystone E,et al.lnfliximab in active early rheumatoid arthritis.Ann Rheum Dis,2004,63:149-155.
  • 10Smolen JS,Han C,Bala M,et al.Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement:a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.Arthritis Rheum,2005,52:1020-1030.

共引文献38

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部